4 Undervalued Pharmaceuticals Stocks for Monday, September 21
Discover the top 4 undervalued Pharmaceuticals stocks for Monday, September 21 based on AAII’s Stock Grades.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Commentary & Analysis
3 Undervalued Pharmaceuticals Stocks for Thursday, August 13
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, August 13 based on AAII’s Stock Grades.Michael Rose
Is Innoviva, Inc. (INVA) Overvalued?
We dive into why Innoviva, Inc. (INVA) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Why Innoviva, Inc.’s (INVA) Stock Is Up 5.51%
As of Thursday, August 06, Innoviva, Inc.’s INVA share price has surged by 5.51%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Innoviva, Inc.'s Q3 Earnings
Innoviva, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (INVA) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | INVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,532.3 | $519.2 | 51% |
|
| Shares Out (Mil) | 73.4 | 42.8 | 56% |
|
| Institutional Ownership | 99.3% | 82.8% | 87% |
|
| Float (Mil) | 67.7 | 44.4 | 53% |
|
| Beta | 0.34 | 0.71 | 20% |
|
| Avg Daily Volume (000s) | 762 | 394 | 65% |
|
| Price Change (52-week) |
22.1% | 60.2% | 71% |
|
| Growth | INVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.1% | 6.1% | 32% |
|
| Net Income (5yr) | 3.9% | (2.0%) | 46% |
|
| EPS (5yr) | 10.3% | 15.0% | 47 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 69.0% | (15.1%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | $0.340 | $2.234 | $2.262 | |
| Month Ago EPS | $0.460 | $1.910 | $2.210 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 3 | 0 | 2 | |
| Three Months Ago EPS | $0.460 | $1.910 | $2.210 | |
| Year/Year Chg | (129.8%) | (32.3%) | (40.3%) | |
| Financials | INVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $440 | $416 | 39% |
|
| Net Income (TTM) (Mil) | $357 | ($11) | 74% |
|
| EPS (TTM) | $4.901 | ($0.700) | 86% |
|
| Operating Cash Flow (TTM) (Mil) | $192 | ($7) | 58% |
|
| Net Cash Flow (TTM) (Mil) | $173 | $6 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $324 | $6 | 54% |
|
| Enterprise Value (Q1) (Mil) | $1,234 | $494 | 43% |
|
| Valuation | INVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.25 | 2.31 | 34% |
|
| P/E | 4.9 | 17.4 | 4% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.5 | 1.1 | 24% |
|
| Ratios | INVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.7% | 69.4% | 83% |
|
| Net Margin | 81.2% | 3.2% | 99% |
|
| ROA | 23.5% | (22.2%) | 97% |
|
| ROE | 36.7% | (21.4%) | 90% |
|
| Liabilities to Assets | 27.6% | 32.8% | 19% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
